Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Monopar Therapeutics Inc. (MNPR)

   0 (0%)
Open: Pre. Close:
High: Low:
Volume: Market Cap: 0M
Monopar Therapeutics Inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers. The company has a collaboration Grupo Espaol de Investigacin en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 8.007 - 8.063 8.063 - 8.107
Low: 7.566 - 7.625 7.625 - 7.671
Close: 7.595 - 7.684 7.684 - 7.753

Technical analysis

as of: 2020-07-17 4:34:14 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 12.04     One year: 14.81
Support: Support1: 6.47    Support2: 5.38
Resistance: Resistance1: 10.31    Resistance2: 12.68
Pivot: 8.08
Moving Average: MA(5): 7.63     MA(20): 8.05
MA(100): 8.35     MA(250):
MACD: MACD(12,26): -0.06     Signal(9): 0.07
Stochastic oscillator: %K(14,3): 14.83     %D(3): 17.85
RSI: RSI(14): 47.93
52-week: High: 48.00  Low: 4.94  Change(%): -71.1
Average Vol(K): 3-Month: 1102  10-Days: 3421

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
MNPR has closed above bottom band by 34.4%. Bollinger Bands are 13.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 14 Aug 2020
80 Biggest Movers From Yesterday - Benzinga

Thu, 13 Aug 2020
70 Stocks Moving In Thursday's Mid-Day Session - Benzinga

Thu, 13 Aug 2020
Monopar Therapeutics Inc. (MNPR) EPS growth this year is -30.90%: Get Prepared for Trading Lift Off - News Daemon

Thu, 13 Aug 2020
Monopar Therapeutics Inc. (NASDAQ:MNPR) is Waving the Bear Flag - The Oracle Dispatch

Thu, 13 Aug 2020
42 Stocks Moving in Thursday's Pre-Market Session - Benzinga

Wed, 12 Aug 2020
Time to Buy Beat-Down Monopar Therapeutics Inc. (MNPR) Stock? Here is the INSIGHT - The InvestChronicle

Financial Analysis

Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NasdaqCM
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 11
Shares Float (M) 2
% Held by Insiders 83.14
% Held by Institutions 0.27
Shares Short (K) 4
Shares Short P. Month (K) 2

Stock Financials

EPS -0.420
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 0.500
Profit Margin
Operating Margin
Return on Assets (ttm) -26.4
Return on Equity (ttm) -43.4
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M) -3
Levered Free Cash Flow (M) -1

Stock Valuations

PE Ratio -18.26
PEG Ratio
Price to Book value 15.34
Price to Sales
Price to Cash Flow -25.88

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.